Bioanalysis

  • Bioanalysis
  • Altasciences' Facilities: Moving in Unison

    Choosing the right bioanalytical platform for your molecule’s intended use and program segment is crucial to obtaining reliable, robust data in a timely manner.

    Microsampling for Pediatric Baricitinib Pharmacokinetics

    Accurate Quantification of ASOs in Mouse Serum Using Microsampling LC-MS/MS

    Design and Validation of a Bioanalytical Method to Support a Clinical Pharmacokinetic Study Involving the Use of Multiple Lots of the Biological Therapeutic Drug

    Since 2004, the average cost of bringing a new drug to market has increased from $800 million to about $2.6 billion, without, for the most part, shorter developmen

    Application of Mitra Microsampling for the Quantitative Bioanalysis of Antisense Oligonucleotides

    Current Strategies for Using Commercial LBA Kit in Regulated Bioanalysis

    In Issue 33 of The Altascientist, we explore how a comprehensive, end-to-end integrated approach to drug development for central nervous system (CNS) therapeutics can take you seamlessly from lead candidate selection to market. 

    Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning.

    With detailed case studies, study considerations, and more, this Issue covers:

    • preclinical safety and toxicity testing,
    • formulation and manufacturing,
    • early-phase clinical trials, and
    • bioanalysis.
     

     

    Biologics are large, complex molecules that can undergo structural changes during the manufacturing process, storage, or administration to patients. This means bioanalysis of biologics is a critical aspect of the drug development process, and one that requires sensitivity, specificity, and selectivity.

    Subscribe to Bioanalysis